332 related articles for article (PubMed ID: 24901803)
21. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
Rojas L; Aizman A; Ernst D; Acuña MP; Moya P; Mellado R; Cerda J
Thromb Res; 2013; 132(6):761-4. PubMed ID: 24521789
[TBL] [Abstract][Full Text] [Related]
22. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients.
Bigos R; Solomon E; Dorfman JD; Ha M
J Surg Res; 2021 Sep; 265():122-130. PubMed ID: 33930618
[TBL] [Abstract][Full Text] [Related]
23. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery.
Simone EP; Madan AK; Tichansky DS; Kuhl DA; Lee MD
Surg Endosc; 2008 Nov; 22(11):2392-5. PubMed ID: 18594915
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of an enoxaparin dosing calculator using burn size and weight.
Faraklas I; Ghanem M; Brown A; Cochran A
J Burn Care Res; 2013; 34(6):621-7. PubMed ID: 24043245
[TBL] [Abstract][Full Text] [Related]
25. Weight-Based Enoxaparin Achieves Adequate Anti-Xa Levels More Often in Trauma Patients: A Prospective Study.
Stutsrim AE; Eady JM; Collum M; Rebo GJ; Rebo KA; Miller PR; Nunn AM
Am Surg; 2021 Jan; 87(1):77-82. PubMed ID: 32915054
[TBL] [Abstract][Full Text] [Related]
26. Enoxaparin and antifactor Xa levels in pediatric acute burn patients.
Brown A; Faraklas I; Ghanem M; Cochran A
J Burn Care Res; 2013; 34(6):628-32. PubMed ID: 24043233
[TBL] [Abstract][Full Text] [Related]
27. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
[TBL] [Abstract][Full Text] [Related]
28. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
29. IV enoxaparin in pediatric and cardiac ICU patients.
Cies JJ; Santos L; Chopra A
Pediatr Crit Care Med; 2014 Feb; 15(2):e95-103. PubMed ID: 24335994
[TBL] [Abstract][Full Text] [Related]
30. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
Ignjatovic V; Najid S; Newall F; Summerhayes R; Monagle P
Br J Haematol; 2010 Jun; 149(5):734-8. PubMed ID: 20346012
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
Pannucci CJ; Fleming KI; Bertolaccini CB; Prazak AM; Huang LC; Pickron TB
JAMA Surg; 2019 Aug; 154(8):697-704. PubMed ID: 31116389
[TBL] [Abstract][Full Text] [Related]
32. Optimal dose of enoxaparin in critically ill trauma and surgical patients.
Rutherford EJ; Schooler WG; Sredzienski E; Abrams JE; Skeete DA
J Trauma; 2005 Jun; 58(6):1167-70. PubMed ID: 15995464
[TBL] [Abstract][Full Text] [Related]
33. Antithrombin concentrate in pediatric patients requiring unfractionated heparin anticoagulation: a retrospective cohort study.
Ryerson LM; Bauman ME; Kuhle S; Bruce AA; Massicotte MP
Pediatr Crit Care Med; 2014 Oct; 15(8):e340-6. PubMed ID: 24901804
[TBL] [Abstract][Full Text] [Related]
34. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events.
Kuhle S; Massicotte P; Dinyari M; Vegh P; Mitchell D; Marzinotto V; Chan A; Pieniaszek H; Mitchell LG
Thromb Haemost; 2005 Dec; 94(6):1164-71. PubMed ID: 16411388
[TBL] [Abstract][Full Text] [Related]
35. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
36. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
[TBL] [Abstract][Full Text] [Related]
37. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
[TBL] [Abstract][Full Text] [Related]
38. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
39. Experience with intravenous enoxaparin in critically ill infants and children.
Crary SE; Van Orden H; Journeycake JM
Pediatr Crit Care Med; 2008 Nov; 9(6):647-9. PubMed ID: 18838932
[TBL] [Abstract][Full Text] [Related]
40. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
